Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909512 | 0.81 | CYP3A4 (0.40) | CYP3A4CYP3A5NFKB1MAPTHTT | |
| SCHEMBL2138820 | 0.80 | CYP3A4 (0.55) | CYP3A4CYP3A5 | |
| SCHEMBL4711968 | 0.78 | CYP3A4 (0.42) | CYP3A4CYP3A5MAPTHTT | |
| SCHEMBL2138189 | 0.76 | CYP3A4 (0.39) | CYP3A4CYP3A5OPRM1CYP2D6 | |
| SCHEMBL975170 | 0.75 | SLC6A9 (0.38) | CYP3A4CYP3A5OPRD1CYP2D6GAA | |
| SCHEMBL2134134 | 0.73 | CYP3A4 (0.40) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL2906358 | 0.73 | CYP3A4 (0.54) | CYP3A4CYP3A5 | |
| SCHEMBL2905660 | 0.73 | CYP3A4 (0.54) | CYP3A4CYP3A5 | |
| SCHEMBL2905664 | 0.73 | CYP3A4 (0.54) | CYP3A4CYP3A5 | |
| SCHEMBL2909506 | 0.73 | CYP3A4 (0.39) | CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| JP-2003525270-A | — | — | 2003-08-26 | — | — | JP | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | claimed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | claimed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | claimed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | claimed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | claimed |
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | disclosed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-7148258-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2006-11-16 | — | — | US | disclosed |
| US-7037944-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-05-02 | — | — | US | disclosed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885ROCK2 4482/4885 |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885ROCK2 4482/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885ROCK2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.